Abstract
The purpose of this research was to investigate the measurement and in vitro delivery implications of multimodal distributions, occurring near or in the respirable range, emitted from pressurized metered-dose inhalers (pMDIs). Particle size distributions of solution pMDIs containing hydrofluoroalkane-134a (HFA-134a) and ethanol were evaluated using 2 complementary particle-sizing methods: laser diffraction (LD) and cascade impaction (CI). Solution pMDIs were formulated from mixtures of HFA-134a (50%–97.5% wt/wt) and ethanol. A range of propellant concentrations was selected for a range of vapor pressures. The fluorescent probe, Rhodamine B, was included for chemical analysis. The complementary nature of LD and CI allowed identification of 2 dominant particle size modes at 1 and 10 μm or greater. Increasing propellant concentrations resulted in increases in the proportion of the size distributions at the 1-μm mode and also reduced the particle size of the larger droplet population. Despite significant spatial differences and time scales of measurement between the particle-sizing techniques, the fine particle fractions obtained from LD and CI were practically identical. This was consistent with LD experiments, which showed that particle sizes did not decrease with increasing measurement distance, and may be explained by the absence of significant evaporation/disintegration of larger droplets. The fine particle fractions (FPFs) emitted from HFA-134a/ethanol solution pMDI can be predicted on the basis of formulation parameters and is independent of measurement technique. These results highlight the importance of presenting particle size distribution data from complementary particle size techniques.
Keywords: metered-dose inhaler, particle size distribution, laser diffraction, HFA-134a, cascade impaction, atomization
Full Text
The Full Text of this article is available as a PDF (377.2 KB).
References
- 1.Alexander DJ. Safety of propellants. J Aerosol Med. 1995;8(suppl 1):29–34. doi: 10.1089/jam.1995.8.suppl_1.s-29. [DOI] [PubMed] [Google Scholar]
- 2.Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm. 1999;186(1):13–30. doi: 10.1016/S0378-5173(99)00134-9. [DOI] [PubMed] [Google Scholar]
- 3.Blondino FE, Byron PR. Surfactant dissolution and water solubilization in chlorine-free liquified gas propellants. Drug Dev Ind Pharm. 1998;24(10):935–945. doi: 10.3109/03639049809097273. [DOI] [PubMed] [Google Scholar]
- 4.Smith IJ. The challenge of reformulation. J Aerosol Med. 1995;8(suppl 1):19–27. doi: 10.1089/jam.1995.8.suppl_1.s-19. [DOI] [PubMed] [Google Scholar]
- 5.Warren SJ, Farr SJ. Formulation of solution metered dose inhalers and comparison with aerosols emitted from conventional suspension systems. Int J Pharm. 1995;124:195–203. doi: 10.1016/0378-5173(95)00076-U. [DOI] [Google Scholar]
- 6.Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med. 1998;92(suppl A):9–15. doi: 10.1016/S0954-6111(98)90212-8. [DOI] [PubMed] [Google Scholar]
- 7.Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104(6):250–252. doi: 10.1016/S0091-6749(99)70041-2. [DOI] [PubMed] [Google Scholar]
- 8.Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122(2):510–516. doi: 10.1378/chest.122.2.510. [DOI] [PubMed] [Google Scholar]
- 9.Dunbar CA, Watkins AP, Miller JF. An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques. J Aerosol Med. 1997;10(4):351–368. doi: 10.1089/jam.1997.10.351. [DOI] [PubMed] [Google Scholar]
- 10.Cheng YS, Fu CS, Yazzie D, Zhou Y. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med. 2001;14(2):255–266. doi: 10.1089/08942680152484180. [DOI] [PubMed] [Google Scholar]
- 11.Polli GP, Grim WM, Bacher FA, Yunker MH. Influence of formulation on aerosol particle size. J Pharm Sci. 1969;58:484–486. doi: 10.1002/jps.2600580422. [DOI] [PubMed] [Google Scholar]
- 12.Williams RO, Liu J. Influence of formulation additives on the vapor pressure of hydrofluoroalkane propellants. Int J Pharm. 1998;166:99–103. doi: 10.1016/S0378-5173(98)00031-3. [DOI] [Google Scholar]
- 13.Tzou T-Z. Density, excess molar volume, and vapor pressure of propellant mixtures in metered-dose inhalers: deviation from ideal mixtures. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, Inc; 1998. pp. 439–443. [Google Scholar]
- 14.Martin A. Physical Pharmacy. 4th ed. Philadephia, PA: Lippincott Williams & Wilkins; 1993. [Google Scholar]
- 15.Smyth HDC, Hickey AJ. Comparative particle size analysis of solution propellant driven metered dose inhalers using cascade impaction and laser diffraction. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory Drug Delivery VIII. Raleigh, NC: DHI Publishing; 2002. pp. 731–734. [Google Scholar]
- 16.United States Pharmacopeia. Rockville, MD: United States Pharmacopeia; 1999. USP24/NF19. General chapter <601> Aerosols; pp. 1895–1895. [Google Scholar]
- 17.Ranucci J. Dynamic plume-particle size analysis using laser diffraction. Pharm Tech. 1992;16:108–108. [Google Scholar]
- 18.Newman SP. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med. 1999;12(suppl 1):S25–31. doi: 10.1089/jam.1999.12.suppl_1.s-25. [DOI] [PubMed] [Google Scholar]
- 19.Clark AR. Metered Atomization for Respiratory Drug Delivery [dissertation] Leicestershire, UK: Loughborough University of Technology; 1991. [Google Scholar]
- 20.Dunbar CA, Watkins AP, Miller JF. Theoretical investigation of the spray from a pressurized metered-dose inhaler. Atomization Sprays. 1997;7(4):417–436. [Google Scholar]
- 21.Finlay WH. The Mechanics of Inhaled Pharmaceutical Aerosols. London, UK: Academic Press; 2001. [Google Scholar]
- 22.Holzner PM, Mueller BW. Particle size determination of metered-dose inhalers by laser diffraction, cascade impaction and liquid impingement. Paper Presented at 1st World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Budapest, 1995: 765–766.
- 23.Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int J Pharm. 2002;249(1–2):219–231. doi: 10.1016/S0378-5173(02)00526-4. [DOI] [PubMed] [Google Scholar]
- 24.Everard ML. CFC transition: the emperors new clothes. Each class of drug deserves a delivery system that meets its own requirements. Thorax. 2000;55:811–814. doi: 10.1136/thorax.55.10.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Leach C. Enhanced drug delivery through reformulating MDIs with HFA propellants: drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, Inc; 1996. pp. 133–144. [Google Scholar]
- 26.Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12(6):1346–1353. doi: 10.1183/09031936.98.12061346. [DOI] [PubMed] [Google Scholar]
- 27.Lefebvre AH. Atomization and Sprays. London, UK: Taylor & Francis; 1989. [Google Scholar]
- 28.Faeth GM, Hsiang LP, Wu PK. Structure and breakup properties of sprays. Int J Multiphase Flow. 1995;21:99–127. doi: 10.1016/0301-9322(95)00059-7. [DOI] [Google Scholar]